- Home
- MEGL vs CLDI Comparison
MEGL vs CLDI Comparison
Compare MEGL & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MEGL | CLDI |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 5.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MEGL | CLDI |
|---|---|---|
| Price | $1.17 | $0.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.1K | ★ 3.6M |
| Earning Date | 04-10-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.19 |
| 52 Week High | $2.62 | $7.32 |
Technical Indicators
Market Signals| Indicator | MEGL | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 31.36 |
| Support Level | $1.16 | N/A |
| Resistance Level | $1.36 | $0.30 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 36.68 | 15.67 |
Price Performance
Historical ComparisonAbout MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.